VaccineIntegrated Nanoplatform for Lactate‐Activatable Chemo/Chemodynamic Therapy and Multiple Immune Regulations of Tumor
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202502439 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Fan Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Advanced Materials and Flexible Electronics (IAMFE), School of Chemistry and Materials Science, Nanjing University of Information Scienc…. Hauptthemen laut MEDLINE: Cancer Vaccines, Lactic Acid, Neoplasms, Nanoparticles. Die Arbeit nennt 42 Literaturangaben. Gefördert von: Postdoctoral Research Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Enhancing the synergistic effect of chemo‐immunotherapy remains a major challenge in the field of cancer treatment. Besides, the premature release of chemotherapeutic or immunotherapeutic agents usually causes systemic immune disorders, leading to the weakness of immunotherapy. Here, a vaccine‐integrated hollow MnO 2 nanoplatform (TMLV), co‐loaded with tirapazamine (TPZ) and lactate oxidase (LOX), is developed to orchestrate lactate‐activatable multiple immune regulations against tumor. Upon accumulation in tumor, TMLV will be degraded by intracellular GSH to release its payloads: TPZ, LOX, Mn 2+ , and vaccine protein (CCV). LOX will catalyze the lactate oxidation to generate H 2 O 2 and exacerbate hypoxia, thereby simultaneously activating Mn 2+ ‐mediated chemodynamic therapy and TPZ‐involved chemotherapy. This process induces a massive release of tumor antigens while circumventing immune damage caused by premature drug release. Subsequently, CCV and Mn 2+ synergistically promote antigen presentation by stimulating Toll‐like receptor signaling and cGAS‐STING pathways in antigen‐presenting cells (APCs), respectively. The activation of cGAS‐STING pathway will further promote the cross‐presentation between activated APCs and CD8 + T cells, significantly strengthening the adaptive immunity. This adjuvant‐free design enabling multi‐pathway immune activation might offer a novel strategy to overcome key challenges in antitumor immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Advanced Materials and Flexible Electronics (IAMFE), School of Chemistry and Materials Science, Nanjing University of Information Science & Technology, Nanjing, 210044, P. R. China.
- Department of Orthopaedics of Changzhou hospital, Nanjing University of Chinese Medicine, Changzhou, 213003, P. R. China.
- Key Laboratory of Biomedical Polymers of Ministry of Education & Department of Chemistry, Wuhan University, Wuhan, 430072, P. R. China.
ORCID-Profile: Fan Gao, Xian-Zheng Zhang
Förderung
- Postdoctoral Research Foundation of China
- National Natural Science Foundation of China
Zitieren
APA
Gao, F., Lu, D., Wei, Y., Xu, J., Lu, X., Ou, C., Zhang, Y., & Zhang, X. Z. (2025). VaccineIntegrated Nanoplatform for Lactate‐Activatable Chemo/Chemodynamic Therapy and Multiple Immune Regulations of Tumor. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202502439
Vancouver
Gao F, Lu D, Wei Y, Xu J, Lu X, Ou C, et al. VaccineIntegrated Nanoplatform for Lactate‐Activatable Chemo/Chemodynamic Therapy and Multiple Immune Regulations of Tumor. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202502439
BibTeX
@article{Gao2025,
author = {Gao, Fan and Lu, Dingyu and Wei, Yiwen and Xu, Jianda and Lu, Xinxin and Ou, Changjin and Zhang, Yizhou and Zhang, Xian-Zheng},
title = {VaccineIntegrated Nanoplatform for Lactate‐Activatable Chemo/Chemodynamic Therapy and Multiple Immune Regulations of Tumor},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202502439}
}
EUVIMED